GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$41.18 USD
+0.86 (2.13%)
Updated Aug 13, 2024 04:00 PM ET
After-Market: $41.19 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$41.18 USD
+0.86 (2.13%)
Updated Aug 13, 2024 04:00 PM ET
After-Market: $41.19 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth B Momentum B VGM
Zacks News
GSK (GSK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
GSK (GSK) closed at $32.24 in the latest trading session, marking a +1.51% move from the prior day.
GSK (GSK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
GSK (GSK) closed the most recent trading day at $31.31, moving +0.19% from the previous trading session.
Will Glaxo (GSK) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Glaxo (GSK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
GSK's RSV Vaccine Candidate Shows High Efficacy in Older Adults
by Zacks Equity Research
GSK's pivotal phase III AReSVi-006 study evaluating its respiratory syncytial virus (RSV) vaccine candidate in adults aged 60 years and above met its primary endpoint.
The Zacks Analyst Blog Highlights Pfizer, BioNTech, Moderna, Merck and GSK
by Zacks Equity Research
Pfizer, BioNTech, Moderna, Merck and GSK are included in this Analyst Blog.
GSK (GSK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
GSK (GSK) closed at $30.65 in the latest trading session, marking a +0.92% move from the prior day.
Pharma Stock Roundup: FDA Oks Omicron Jabs for Kids, MRK, MRNA Partner for Cancer Jab
by Kinjel Shah
FDA grants emergency approval to Pfizer (PFE) and Moderna's (MRNA) Omicron BA.4, BA.5 adapted COVID-19 booster for use in kids. Merck (MRK) and Moderna to jointly develop an mRNA-based cancer vaccine.
Gilead (GILD) Trodelvy Label Expansion sBLA Gets Priority Review
by Zacks Equity Research
Gilead's (GILD) efforts to expand Trodelvy's label progress, as the FDA accepts sBLA for the same and grants Priority Review.
Gilead (GILD) Up 2.6% in 3 Months: Will the Momentum Continue?
by Zacks Equity Research
Gilead (GILD) is having a good run despite the volatility on a string of positive updates.
GSK's (GSK) Boostrix Gets FDA Nod for Pertussis in Newborns
by Zacks Equity Research
Following FDA approval, GSK's (GSK) Boostrix is the first vaccine in the United States specifically approved during pregnancy to prevent disease in young infants by vaccinating pregnant women.
GSK (GSK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
GSK (GSK) closed the most recent trading day at $30.11, moving +0.37% from the previous trading session.
Vir Biotechnology (VIR) Gains 11% This Week on BARDA Contract
by Zacks Equity Research
VIR shares gain following a multi-year contract from BARDA for the development of influenza and other emerging infectious disease or medical countermeasure candidates.
GSK's (GSK) PD-1 Inhibitor Drug Meets Lung Cancer Study Goal
by Zacks Equity Research
GSK's (GSK) mid-stage study, evaluating the combination of its cancer drug Jemperli with chemotherapy in non-small cell lung cancer, meets the primary endpoint of objective response rate.
GSK (GSK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, GSK (GSK) closed at $30.41, marking a -0.98% move from the previous day.
GSK's Key Drugs to Drive Sales in a Sluggish Second Half
by Zacks Equity Research
GSK's specialty products like Dovato, Nucala, Trelegy Ellipta, Shingrix are driving sales, making up for the lower sales of established drugs due to generic erosion.
Sanofi (SNY) Relies on Dupixent and Vaccines to Drive Growth
by Zacks Equity Research
Dupixent has become the key top-line driver for Sanofi (SNY). Sanofi possesses a leading vaccine portfolio, which has become the primary top-line driver. Its R&D pipeline is strong.
Here is What to Know Beyond Why GSK PLC Sponsored ADR (GSK) is a Trending Stock
by Zacks Equity Research
Glaxo (GSK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
GSK (GSK) Stock Moves -0.34%: What You Should Know
by Zacks Equity Research
GSK (GSK) closed at $29.36 in the latest trading session, marking a -0.34% move from the prior day.
Spero (SPRO) Skyrockets 168% on Licensing Deal With GSK
by Zacks Equity Research
The exclusive licensing agreement with GSK will fund Spero's (SPRO) existing operations and extend its current cash runway beyond 2024.
Pharma Stock Roundup: EU Nod to AZN & RHHBY Drugs, FDA Updates for LLY & MRK
by Kinjel Shah
Roche's (RHHBY) eye drug, Vabysmo and AstraZeneca's (AZN) asthma drug Tezspire get approval in Europe. The FDA approves expanded use of Lilly's (LLY) cancer drug, Retevmo.
GSK (GSK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, GSK (GSK) closed at $30.01, marking a +0.81% move from the previous day.
AstraZeneca's (AZN) Asthma Drug Tezepelumab Gets Nod in Europe
by Zacks Equity Research
AstraZeneca's (AZN) Tezspire is the only biologic medicine approved in Europe to treat severe asthma with no phenotype limitation and irrespective of biomarker levels.
Merck (MRK) Resumes HIV Studies on Islatravir With Lower Dose
by Zacks Equity Research
Merck's (MRK) new phase III studies are set to evaluate a once-daily oral combination of doravirine and a lower dose of islatravir
Is Trending Stock GSK PLC Sponsored ADR (GSK) a Buy Now?
by Zacks Equity Research
Glaxo (GSK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Company News for Sep 20, 2022
by Zacks Equity Research
Companies in The News Are: WIX,COIN,TBPH,GSK,MRNA